AMSilk secures funding from existing investors ATHOS, MIG Capital, and Novo Holdings to support industrial scale-up. The €52m in funds will meet global demand for silk-based protein materials and establish new production facilities for commercial traction.

AMSilk’s CFO expresses gratitude for shareholder support and confidence in the company’s technology. The investment will help AMSilk scale production and establish resilient supply chains. Chairman of the advisory board highlights the high demand for products and plans to massively scale-up production.

Several multi-year production agreements have been finalized by AMSilk, ensuring long-term industrial output and supply reliability. Dedicated production facilities enable consistent quality and reliability across AMSilk’s product portfolio, enhancing scalability and commercial viability.

AMSilk’s silk-based protein technology reprograms microorganisms to create sustainable biomaterials used in textiles and consumer care. The fully biodegradable materials are 100% protein-based and microplastic-free, meeting the demand for eco-friendly solutions in the fashion and automotive industries.

AMSilk strengthens its commercial presence through strategic partnerships with global fashion brands following successful financing. A recent collaboration with Ajinomoto Foods Europe aims to bio-manufacture silk proteins, further expanding AMSilk’s reach and capabilities in the biotech sector.

Read more at Yahoo Finance: AMSilk will use $61m funding to meet growing silk-based biotech demand